AI blood test could spare some breast cancer patients extra chemo

NCT ID NCT04874064

Recruiting now Knowledge-focused Sponsor: Jewish General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop a blood test that uses artificial intelligence to analyze tumor material in the blood of people with triple negative breast cancer. The goal is to better predict which patients need more chemotherapy after surgery and which can safely avoid it. Researchers will collect blood and tissue samples from 130 participants to build a test that guides treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E1, Canada
St. Joseph's Health Care London
RECRUITING

London, Ontario, N6A 4V2, Canada
The Ottawa Hospital Cancer Center
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.